Overall Score

Revenue Model

OCUL remains a product-driven ophthalmology business with very high gross margin (87.1% TTM), indicating strong pricing power on its marketed therapies.

Revenue generation is still constrained by a very low asset turnover (0.08x) and high price-to-sales multiple (42.8x), implying the market is pricing in substantial future growth.

Profitability

The company is still unprofitable on a TTM basis, with operating margin at -6.0% and net margin at -5.8%.

Returns remain deeply negative, including ROE of -59.9% and ROIC of -50.2%, showing the business is not yet converting its gross margin into bottom-line earnings.

Cash Generation

OCUL continues to generate negative operating cash flow and free cash flow on a TTM basis, with FCF yield at -11.5%.

Despite negative cash generation, the balance sheet remains liquid with a current ratio of 13.1x and cash ratio of 12.2x, which provides near-term flexibility.

Balance Sheet

The balance sheet remains strong, with low leverage metrics such as debt-to-equity of 0.15x and debt-to-assets of 11.8%.

Liquidity is ample, supported by cash per share of $2.66 versus book value per share of $2.31, suggesting a sizable cash cushion relative to equity.

Competitive Position

OCUL’s high gross margin suggests differentiated products and some competitive strength in its niche ophthalmology market.

However, the business still shows weak operating efficiency and negative returns, so the moat is not yet translating into durable economic profits.